Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

303
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
303
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.2K
Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

400
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
400
Asthma-IV: Nursing Management01:30

Asthma-IV: Nursing Management

3.9K
The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...
3.9K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

523
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
523
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

868
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
868

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of GBA1 status and sex with depression severity and progression in Parkinson's disease.

NPJ Parkinson's disease·2026
Same author

L-Dopa/Carbidopa intestinal gel infusion in advanced Parkinson's disease: real-life mobility insights from wearable sensors.

Frontiers in neurology·2026
Same author

Levodopa-induced dyskinesia is associated with worse gait and balance in Parkinson's disease.

Journal of neural transmission (Vienna, Austria : 1996)·2026
Same author

Integrative Transcriptomics Uncovers IFN-β Signature and IFITM3 as Putative Molecular Mediator in MS.

International journal of molecular sciences·2026
Same author

Web-based family-reported outcomes to assess family functioning in multiple sclerosis: an Italian multicenter digital survey.

International journal of medical informatics·2026
Same author

Correction: Enhancing the endocannabinoid system to treat residual disease in relapse-free multiple sclerosis.

Frontiers in neurology·2026

Related Experiment Video

Updated: Mar 3, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.9K

Natalizumab in Multiple Sclerosis: Long-Term Management.

Marinella Clerico1, Carlo Alberto Artusi2, Alessandra Di Liberto3

  • 1Clinical and Biological Sciences Department, University of Torino, Orbassano (TO) 10043, Italy. marinella.clerico@unito.it.

International Journal of Molecular Sciences
|May 5, 2017
PubMed
Summary

Natalizumab effectively treats MS but carries a risk of PML brain infection. Strategies for continuing or stopping treatment after 24 doses are unclear, balancing PML risk with MS activity.

Keywords:
long term safetynatalizumabnatalizumab discontinuationnatalizumab managementprogressive multifocal leukoencephalopathytherapeutic switch

More Related Videos

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
08:57

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

27.9K
Systemic Injection of Neural Stem/Progenitor Cells in Mice with Chronic EAE
09:24

Systemic Injection of Neural Stem/Progenitor Cells in Mice with Chronic EAE

Published on: April 15, 2014

18.2K

Related Experiment Videos

Last Updated: Mar 3, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.9K
Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
08:57

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

27.9K
Systemic Injection of Neural Stem/Progenitor Cells in Mice with Chronic EAE
09:24

Systemic Injection of Neural Stem/Progenitor Cells in Mice with Chronic EAE

Published on: April 15, 2014

18.2K

Area of Science:

  • Neurology
  • Immunology
  • Infectious Diseases

Background:

  • Natalizumab is a highly effective monoclonal antibody for relapsing remitting multiple sclerosis (RRMS).
  • Concerns exist regarding progressive multifocal leukoencephalopathy (PML), a JC virus (JCV) brain infection, associated with natalizumab use, especially after 24 doses or with prior immunosuppression.
  • Patients on long-term natalizumab, with prior immunosuppressive drug use, or JCV antibody-positive require reassessment of treatment continuation versus withdrawal.

Purpose of the Study:

  • To review strategies for managing natalizumab treatment after 24 doses.
  • To analyze approaches for mitigating progressive multifocal leukoencephalopathy (PML) risk while preventing clinical and radiological rebound activity.
  • To evaluate outcomes of natalizumab continuation, discontinuation with therapeutic suspension, or switching to alternative MS treatments.

Main Methods:

  • Review of clinical trials and case reports.
  • Analysis of natalizumab continuation versus discontinuation strategies.
  • Examination of outcomes following switches to other first or second-line multiple sclerosis (MS) treatments.

Main Results:

  • Discontinuing all MS treatment after natalizumab increases the occurrence of MS activity.
  • Outcomes following therapeutic switches after natalizumab are not uniform.
  • No established guidelines exist for natalizumab treatment post-24 administrations; decisions rely on neurologist expertise and patient factors.

Conclusions:

  • Managing natalizumab treatment beyond 24 doses presents a challenge in balancing PML risk with MS disease control.
  • Current evidence does not support a definitive strategy for treatment continuation or switching.
  • Individualized patient care, considering clinical features and neurologist experience, guides decisions in the absence of clear guidelines.